Targeting the SH2-Kinase Interface in Bcr-Abl Inhibits Leukemogenesis

Florian Grebien, Oliver Hantschel, John Wojcik, Ines Kaupe, Boris Kovacic, Arkadiusz M. Wyrzucki, Gerald D. Gish, Sabine Cerny-Reiterer, Akiko Koide, Hartmut Beug, Tony Pawson, Peter Valent, Shohei Koide, and Giulio Superti-Furga.

1CeMM - Research Center for Molecular Medicine of the Austrian Academy of Sciences, Lazarettgasse 14, AKH BT 25.3, 1090 Vienna, Austria
2The University of Chicago, 929 East 57th Street, Chicago, IL 60637, USA
3Research Institute for Molecular Pathology, Dr. Bohr Gasse 7, 1030 Vienna, Austria
4Intercollegiate Faculty of Biotechnology, University of Gdańsk-Medical University of Gdańsk, 80-210 Gdańsk, Poland
5Samuel Lunenfeld Research Institute, Mount Sinai Hospital, 600 University Avenue, Toronto, Ontario M5G 1X5, Canada
6The Department of Molecular Genetics, University of Toronto, Toronto, Ontario M5S 1A8, Canada
7Department of Internal Medicine I, Division of Hematology and Hemostaseology and Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, 1090 Vienna, Austria
8These authors contributed equally to this work
9Present address: Ecole polytechnique fédérale de Lausanne (EPFL), Swiss Institute for Experimental Cancer Research (ISREC), 1015 Lausanne, Switzerland
10Present address: Translational Oncology, Institute of Animal Breeding and Genetics, Veterinary Medical University of Vienna, A-1210 Vienna, Austria
*Correspondence: oliver.hantschel@epfl.ch (O.H.), gsuperti@cemm.oeaw.ac.at (G.S.-F.)

DOI 10.1016/j.cell.2011.08.046
Open access under CC BY-NC-ND license

SUMMARY

Chronic myelogenous leukemia (CML) is caused by the constitutively active tyrosine kinase Bcr-Abl and treated with the tyrosine kinase inhibitor (TKI) imatinib. However, emerging TKI resistance prevents complete cure. Therefore, alternative strategies targeting regulatory modules of Bcr-Abl in addition to the kinase active site are strongly desirable. Here, we show that an intramolecular interaction between the SH2 and kinase domains in Bcr-Abl is both necessary and sufficient for high catalytic activity of the enzyme. Disruption of this interface led to inhibition of downstream events critical for CML signaling and, importantly, completely abolished leukemia formation in mice. Furthermore, disruption of the SH2-kinase interface increased sensitivity of imatinib-resistant Bcr-Abl mutants to TKI inhibition. An engineered Abl SH2-binding fibronectin type III monobody inhibited Bcr-Abl kinase activity both in vitro and in primary CML cells, where it induced apoptosis. This work validates the SH2-kinase interface as an allosteric target for therapeutic intervention.

INTRODUCTION

The deregulated, constitutively activated tyrosine kinase Bcr-Abl is expressed from the Philadelphia chromosome after the t(9;22) chromosomal translocation that leads to the fusion of the breakpoint cluster region (BCR) gene and the Abelson tyrosine kinase (ABL1) (Wong and Witte, 2004). The defining molecular event of chronic myelogenous leukemia (CML) in humans is the expression of Bcr-Abl, which is sufficient for the initiation and maintenance of CML-like disease in mouse models (Daley et al., 1990). Bcr-Abl activates a large number of signaling pathways that lead to uncontrolled proliferation, inhibition of apoptosis, and block of myeloid differentiation. Many of these pathways are thought to act in a redundant fashion, as only a few signaling components have thus been reported to be critical for Bcr-Abl-mediated oncogenic transformation. These include the transcription factors STAT5 and Myc, as well as the adaptor protein Gab2 (Nieborowska-Skorska et al., 1999; Hoelbl et al., 2010; Sattler et al., 2002).

Inhibition of Bcr-Abl tyrosine kinase activity by the highly specific Bcr-Abl inhibitor imatinib (Gleevec) leads to durable cytogenetic and molecular remissions in the majority of CML patients in the early chronic phase of the disease and is superior to previous therapies in advanced stage CML (Hochhaus et al., 2009; Deininger et al., 2005). The occurrence of imatinib resistance—mainly caused by point mutations in the Bcr-Abl kinase domain—leads to patient relapse, bears the risk of disease progression, and resulted in the development and rapid approval of the second-generation inhibitors nilotinib and dasatinib that target most imatinib-resistant Bcr-Abl variants (Shah and Sawyers, 2003; Quintás-Cardama et al., 2007). However, unsatisfactory responses in advanced disease stages, resistance, and problematic long-term tolerability of all three Bcr-Abl inhibitors remain major clinical problems (Jabbour et al., 2010). All approaches aimed at targeting the ATP-binding pocket of the Bcr-Abl kinase domain alone do not target the disease-initiating leukemic stem cells, and thus, patients are not cured from CML (Perrotti et al., 2010). Combination therapy of imatinib with drugs that target downstream
signaling components of Bcr-Abl yielded promising results in preclinical studies (reviewed in Deininger et al., 2005). Still, these approaches have currently not been followed up further, as restoration of Bcr-Abl activity by resistance mutations appears to be dominant and override additive or synergistic inhibitory effects of the second drug (Deininger et al., 2005). For these reasons, approaches to target additional sites on Bcr-Abl itself in combination with the commonly targeted ATP-binding pocket may result in superior future therapeutic options.

Studies on the structure and dynamics of c-Abl/Bcr-Abl regulation have identified key regulatory mechanisms (reviewed in Hantschel and Superti-Furga, 2004). Binding of the N-terminal myristoyl moiety to a unique binding pocket in the c-Abl kinase domain was found to be critical for autoinhibition (Hantschel et al., 2003, Nagar et al., 2003). The myristoyl pocket was targeted by the non-ATP-competitive compound GNF-2/GNF-5 that led to inhibition of pan-TKI resistant Bcr-Abl variant T315I in a mouse model in combination with nilotinib (Zhang et al., 2010).

SH2 domains constitute one of the largest families of eukaryotic protein-protein interaction domains and bind phosphorytrosine moieties with a certain sequence specificity (Pawson et al., 2001). Aside from their well-described role in mediating intramolecular protein interactions, the SH2 domains in certain cytoplasmic tyrosine kinases, like c-Abl and Fes, were shown to activate the adjacent tyrosine kinase domain (Filippakopoulos et al., 2008). The ability of the Abl SH2 to stimulate kinase activity was dependent on the establishment of a tight interface between the SH2 domain and the N-terminal lobe of the kinase domain (Filippakopoulos et al., 2008; Nagar et al., 2006). Mutations in the SH2 domain that disrupt this SH2-kinase domain interface resulted in severe impairment of kinase activity. Thus, correct positioning of the SH2 and kinase domain modules appears to be critical for efficient activation of cytoplasmic tyrosine kinases (Filippakopoulos et al., 2008).

In the oncogenic fusion Bcr-Abl, the Bcr moiety contains important regulatory elements that contribute to constitutive activation and cellular transformation. The Grb2 docking site (Y177 in Bcr) and the coiled-coil oligomerization domain were shown to support Bcr-Abl leukemogenicity (McWhirter et al., 1993; Million and Van Etten, 2000). Therefore, whether or not SH2-mediated allosteric activation of the kinase domain is operable on the already highly activated Bcr-Abl fusion kinase or even affects its leukemogenicity were entirely unclear. Therefore, we set out to understand the functional role of the SH2-kinase domain interface in the context of Bcr-Abl.

The SH2 domain of Bcr-Abl is a critical residue for the integrity of the active conformation of Bcr-Abl

The SH2 domain is thought to act as an intramolecular allosteric activator of the tyrosine kinase domain in the protooncogenic kinases Fes and c-Abl (Filippakopoulos et al., 2008, 2009). Recently, a mutation of threonine 231 (Thr231) in the SH2 domain of the Bcr-Abl protein was identified in imatinib-treated patients and implicated in causing imatinib resistance (Sherbenou et al., 2010). The T231R mutation may stabilize the SH2-kinase domain interface by the formation of an additional ionic interaction with Glu294 in the N-lobe of the kinase domain (Figure 1A and Sherbenou et al., 2010). In contrast, mutation of isoleucine 164 (Ile164), located in the αA-βB-loop of the Abl SH2 domain, to glutamate (Ile164E) may nullify the allosteric activation of the Abl kinase by the SH2 domain by disrupting the SH2-kinase domain interface (Filippakopoulos et al., 2008; Nagar et al., 2006 and Figure 1A). These two observations may suggest a possible role of the Bcr-Abl SH2-kinase domain interface for the activity of the oncogene and even in CML pathobiology.

We introduced the I164E and T231R single mutations and the I164E/T231R double mutation into Bcr-Abl. Upon expression in HEK293 cells, global tyrosine phosphorylation, Bcr-Abl autophosphorylation (on Tyr412 in the activation loop and on Tyr245 in the SH2-kinase linker), and in vitro tyrosine kinase activity were reduced in the I164E but increased in the T231R mutant. The I164E mutation was dominant over the T231R mutation, consistent with the proposed disrupting effect of the I164E mutation versus the stabilizing role of the T231R mutation (Figures 1B and 1C). In contrast, levels of phosphorylated Tyr177 in the Bcr part of Bcr-Abl, a site thought to be phosphorylated by Src kinases, were slightly higher in the T231R mutant. This might suggest higher Src activity in the presence of the T231R mutation (Figure 1B).

To study the structural role of Ile164 in more detail, we mutated ile164 to different polar/charged amino acids (Glu, Gln, Thr, Asp, or Lys) or to Ala. All mutations led to a strong reduction of Abl kinase activity and cellular transformation. The Grb2 docking site (Y177 in Bcr) and the coiled-coil oligomerization domain were shown to support Bcr-Abl leukemogenicity (McWhirter et al., 1993; Million and Van Etten, 2000). Therefore, whether or not SH2-mediated allosteric activation of the kinase domain is operable on the already highly activated Bcr-Abl fusion kinase or even affects its leukemogenicity were entirely unclear. Therefore, we set out to understand the functional role of the SH2-kinase domain interface in the context of Bcr-Abl.

The data presented here show that the SH2-kinase domain interface is critical for Bcr-Abl activity both in vitro and in cells. Disruption of this interface abolished the development of CML in a mouse bone marrow transplantation model and enhanced TKI sensitivity of nonmutated and TKI-resistant Bcr-Abl forms. Finally, an engineered high-affinity Abl SH2 domain-binding protein targeted to the SH2-kinase interface was found to strongly inhibit Bcr-Abl activity in vitro and to induce apoptosis in CML cell lines as well as in primary CML cells, demonstrating the potential druggability of this interface.
Figure 1. Structure-Function Analysis of the SH2-Kinase Domain Interface in Bcr-Abl

(A) Cartoon diagram of the active SH2-kinase domain unit of Abl. Critical residues involved in the SH2-kinase domain interface that are discussed in the text are highlighted.

(B) HEK293 cells were transiently transfected with Bcr-Abl WT, I164E, T231R, or I164E/T231R. Total protein extracts (left panels) and Abl immunoprecipitates (right panels) were analyzed by immunoblotting using the indicated antibodies.

(C) Abl immunoprecipitates were assayed for catalytic activity using an optimal Abl substrate peptide, and total autophosphorylation was quantified. Kinase activity and autophosphorylation of Bcr-Abl WT were set to 1. The bar graph shows averages ± standard deviation (SD) from two independent experiments done in triplicate.

See also Figure S1.
of the SH2-kinase domain interface also influences the cellular activity of Bcr-Abl.

As the canonical function of the SH2 domain is phosphotyrosine binding, we analyzed whether the I164E mutation would interfere with phosphopeptide-SH2 interactions (Pawson et al., 2001). Recombinant WT and I164E-mutated Abl SH2 domains displayed indistinguishable low micromolar binding constants for an optimal Abl SH2-domain phosphopeptide ligand (Figure S2). In contrast, Abl SH2 domains bearing the FLVRE \( \rightarrow \) S mutants R171L or S173N were unable to bind tyrosine-phosphorylated peptides (Figure S2 and data not shown). Together these data show that the I164E mutant does not compromise phosphotyrosine binding or structural integrity of the SH2 domain. Nonetheless, in the context of full-length Abl kinase, the I164E mutant was as defective as the FLVRE \( \rightarrow \) S mutant S173N in multisite phosphorylation of paxillin (Figure S2). This shows that aside from the intrinsic reduction in in vitro and cellular kinase activity, disruption of the SH2-kinase interface also interferes with multisite phosphorylation of Abl substrates, even though the phosphotyrosine peptide-binding properties of the SH2 domain are retained in Abl I164E. In addition, this indicates that the correct positioning of the SH2 domain may

Figure 2. The SH2-Kinase Domain Interface in Bcr-Abl Is Both Necessary and Sufficient for High Catalytic Activity of the Enzyme

(A) Immunoprecipitated Bcr-Abl WT and I164E proteins were assayed for catalytic activity in the presence of the indicated concentrations of an optimal Abl substrate peptide containing a single tyrosine phosphorylation site. Averages of three replicates are plotted. The \( K_m \) and \( v_{max} \) values were calculated after fitting the data to the Michaelis-Menten equation.

(B) Bcr-Abl WT and I164E constructs were coexpressed with HA-tagged paxillin in HEK293 cells, and total protein extracts were analyzed by immunoblotting using the indicated antibodies.

(C) The indicated constructs were transiently transfected in HEK293 cells along with HA-paxillin. FRB-FKBP dimerization was induced by treating cells with AP21967. Total cell lysates were analyzed by immunoblotting using the indicated antibodies. See also Figure S2.
just be as important as the ability of the SH2 domain to bind primed tyrosine-phosphorylated substrates for further rounds of phosphorylation.

**Induced Tethering of the SH2 Domain to the Kinase Domain Activates Abl and Depends on Ile164**

In order to assess its potential for pharmacological exploitation, we further investigated the molecular mechanism of the positive effect of the SH2 domain on kinase activity. We made use of the FKBP-FRB fusion protein system, in which the SH2 and kinase domains of Abl are expressed separately but can be induced to physically associate upon addition of rapamycin (Belshaw et al., 1996) (Figure 2C). Induced tethering of the Abl SH2 domain to the Abl kinase domain led to an unexpectedly strong increase in phosphorylation of cotransfected paxillin and in total cellular tyrosine phosphorylation (Figure 2C). The effect was reliant on the presence of both protein components and on the dimerization-inducing drug. Importantly, this effect was entirely dependent on the SH2-kinase interface, as mutation of Ile164 abolished the stimulatory effect. This provided conclusive evidence that docking of the SH2 domain is sufficient for the observed positive allosteric effect on kinase activity and could thus represent a targetable interaction.

**The Bcr-Abl SH2-Kinase Interface Is Critical for the Transformation of Primary Murine Hematopoietic Cells and Leukemia Formation In Vivo**

We next determined whether mutation of the SH2-kinase domain interface had an effect on oncogenic transformation and leukemogenicity. Primary murine bone marrow hematopoietic cells transduced with Bcr-Abl WT were able to form colonies in the absence of cytokines in semisolid media (Figure 3A). In contrast, this transforming capability was dramatically reduced in cells expressing Bcr-Abl I164E (Figure 3A).

We then tested whether this reduction was also manifest in an in vivo model of Bcr-Abl-induced leukemia (Daley et al., 1990). Equal numbers of Bcr-Abl WT- and Bcr-Abl I164E-transduced hematopoietic stem cells were injected into lethally irradiated recipient mice (Figure 3B). Mice transplanted with Bcr-Abl-expressing cells developed an aggressive myeloproliferative disorder, leading to death of all animals within 3 weeks (Figure 3B). These mice displayed massively infiltrated spleen and liver and loss of normal organ architecture (Figure 3C). In contrast, all mice transplanted with Bcr-Abl I164E-expressing cells remained alive for the 120 days of the study (Figure 3B). After this period, no obvious pathological alterations in the liver or spleen were detected despite confirmation of the presence of Bcr-Abl I164E-transduced...
cells in all lineages in peripheral blood, bone marrow, and spleen (Figures 3C and 3D and data not shown). On one hand, this indicates a lack of oncogenic properties of Bcr-Abl I164E that are necessary to induce a fatal leukemia, but it rules out a possible defect in engraftment and/or hematopoietic differentiation caused by the I164E mutation. Together, our results indicate a crucial role for the SH2-kinase domain interface in Bcr-Abl-mediated leukemic transformation.

Bcr-Abl I164E Confers Growth-Factor Independence to Ba/F3 and UT-7 Cells despite Reduced Kinase Activity

To assess cellular effects and downstream signaling of the Bcr-Abl I164E mutation, we engineered the murine IL-3-dependent cell line Ba/F3 and the human GM-CSF-dependent cell line UT-7 to express Bcr-Abl WT and Bcr-Abl I164E. In both cell lines, we consistently observed higher expression levels of Bcr-Abl I164E as compared to Bcr-Abl WT, despite equal virus titers used (Figure 4A and data not shown). Nevertheless, global tyrosine phosphorylation was still lower in cells expressing Bcr-Abl I164E (Figure 4A). Single-cell clone pairs, initially selected for equal expression levels of Bcr-Abl WT and I164E, quickly showed increased Bcr-Abl I164E expression within a few passages (data not shown).

A widely used read-out of Bcr-Abl activity is the ability to confer cytokine-independent growth to Ba/F3 or UT-7 cells. Despite the complete lack of leukemogenic activity of Bcr-Abl I164E (see Figure 3), we observed that Bcr-Abl I164E was equally potent in transforming Ba/F3 or UT-7 cell lines to cytokine
by others and us to monitor different conformational states of
the tyrosine kinase domain and not affecting phosphotyrosine
binding of the SH2 domain could have such a dramatic effect
on the oncogenic activity of Bcr-Abl. Given this crucial function,
we investigated the downstream signaling events that may be
involved. We tested some major phosphorylation events in Ba/
F3 cells, as well as in human U937 cells. As already observed
in HEK293 cells, mutation of Ile164 led to a strong reduction of
global tyrosine phosphorylation and phosphorylation of Tyr412
in the activation loop of Bcr-Abl (Figures 4A and 4D). Important
signaling mediators downstream of Bcr-Abl include the phos-
phorylation and activation of STAT5, Akt, and Erk1/2 (Ren,
2005). We observed a strong reduction in tyrosine phosphoryla-
tion of STAT5 and CrkL in cells expressing Bcr-Abl I164E as
compared to Bcr-Abl WT (Figures 4C, 4D, and S3). As activation
of STAT5 is required for the induction and maintenance of
CML by Bcr-Abl (Nieborowska-Skorska et al., 1999; Hoelbl
et al., 2010), it is tempting to speculate that the inability of Bcr-
Abl I164E to induce CML may mainly be caused by its inability
to activate STAT5.

Surprisingly, despite the strong effect on Bcr-Abl activity,
the I164E mutation had no effect on Erk1/2 and Akt phosphoryla-
tion or other MAPK or PI3K pathway members (Figures 4C and 4D
and data not shown). This is in line with comparable levels of
phosphorylated Tyr177 in Bcr-Abl, which was shown to be crit-
ical for PI3K and MAPK pathway activation (Figure 1B) (Sattler
et al., 2002). Thus, interference with the SH2-kinase domain
interface appears to result in a complex rewiring of the signaling
network with specific downregulated events rather than general
attenuation of signaling, suggesting that uncoupling of the
SH2-kinase module may generate a not only quantitatively but
also qualitatively impaired abnormal Bcr-Abl output. Furthermore,
these data are consistent with different thresholds in
Bcr-Abl activity that are required for full signaling output, with
STAT5 activation being a critical event that is highly sensitive
to disruption of the SH2-kinase domain interface.

Disruption of the SH2-Kinase Domain Interface
Sensitizes Bcr-Abl WT and Drug-Resistant
Forms to TKI Inhibition
Pharmacological interference with the SH2-kinase domain inter-
action surface would be particularly attractive if it could alter the
sensitivity of Bcr-Abl to existing TKIs. We tested the sensitivity of
Bcr-Abl I164E toward the CML TKIs imatinib and dasatinib in
in vitro kinase assays (Figures 5A and 5B). Whereas imatinib
and nilotinib exclusively bind Bcr-Abl when its activation loop
is not phosphorylated, binding of dasatinib requires an active
conformation (Schindler et al., 2000; Vajpai et al., 2008).
Therefore, different sensitivities to the two classes have been used
by others and us to monitor different conformational states of the
target enzymes (De Keersmaecker et al., 2008). We observed
a 4-fold increase in sensitivity of Bcr-Abl I164E for imatinib,
whereas no differences were observed in response to dasatinib
(Figures 5A and 5B). In line with this, the sensitivity of Ba/F3 cells
expressing Bcr-Abl I164E for nilotinib was increased 3-fold
(Figure 5C). We next addressed whether disruption of the SH2-
kinase domain interface also sensitized TKI-resistant mutants
to nilotinib inhibition. Introduction of the I164E mutation in the
imatinib-resistant Bcr-Abl clones H396R or E255K also in-
creased the nilotinib sensitivity of these mutants 3-fold (Fig-
ure 5D and data not shown).

The T315I mutation in Bcr-Abl is the only mutation that is resis-
tant to imatinib, nilotinib, and dasatinib. At concentrations that
only marginally inhibited Bcr-Abl T315I, nilotinib caused a
dramatic reduction in the in vitro tyrosine kinase activity in the
Bcr-Abl T315I/I164E double mutant (Figure 5E). Finally, the
I164E mutation also increased the sensitivity of Bcr-Abl T315I-
expressing Ba/F3 cells toward the allosteric myristate-binding
pocket inhibitor GNF-2 (Zhang et al., 2010 and Figure 5F). These
results extend the recently proposed cooperativity between the
myristate pocket and the ATP-binding site (Zhang et al., 2010)
to the SH2-kinase domain interface and indicate that disruption
of the SH2-kinase domain interface not only sensitizes Bcr-Abl WT
to imatinib/nilotinib but could also be used to enhance inhibition
of TKI-resistant Bcr-Abl mutants.

Targeting of the Bcr-Abl SH2-Kinase Interface
using Monobodies
To test whether the SH2-kinase interface can be targeted using
an inhibitor in trans, we generated single-domain binding pro-
teins based on the fibronectin type III domain (FN3), termed
monobodies, that target the Abl SH2 domain (Koidie and Koidie,
2007; Wojcik et al., 2010). We have previously described the
Abl SH2-binding monobody HA4, which acts as a competitive
inhibitor of phosphotyrosine binding (Wojcik et al., 2010). Using
HA4 as a competitor in phage-display library sorting, we identified
an Abl SH2 monobody, designated 7c12, that bound to a distinct
site. 7c12 binds the Abl SH2 domain with a dissociation constant
(KD) of ~50 nM (Figure S4 and data not shown). In in vitro kinase
assays, 7c12 inhibited kinase activity of Bcr-Abl WT and T315I,
but not of Bcr-Abl I164E or Bcr-Abl T315I/I164E (Figures 6A
and S4). Although the effect was mild, it was statistically signifi-
cant and did not occur with a recombinant control protein, which
does not bind the Abl SH2 domain. This suggested a possible
involvement of the Bcr-Abl SH2-kinase domain interface in
7c12 binding. In fact, the I164E mutation reduced binding of
7c12 by a factor of ~400 (Figure 6B).

Crystal Structure of the Abl SH2 Domain-7c12
Monobody Complex
To elucidate the molecular details of the 7c12-Abl SH2 interac-
tion, we determined the crystal structure of the complex at
2.1 Å resolution (PDB ID: 3T04; Table S1; Figures 6C and S5).
The asymmetric unit consists of a single monobody-SH2 domain
complex (Figures 6C and S5A). The 7c12 monobody and the Abl
SH2 domain contribute nearly equally to the ~1340 Å² of surface
area buried in the complex. The diversified loops contribute
nearly 75% of the binding interface with each of the three loops
making substantial contributions (91, 178, and 234 Å² for the BC,
The D strand of the monobody scaffold also makes substantial contribution to the interface. It packs against the C-terminal tail of the SH2 domain through an intermolecular $\beta$ sheet (Figure S5A, red box and S5B). Outside of these backbone-mediated interactions, the interface is dominated by hydrophobic contacts between monobody loop residues and two surface concavities on either side of $\beta$ strand B of the SH2 domain. At the end of the monobody D strand, the DE loop forms a hairpin that packs against one of these concave surfaces that is formed by the $\beta$B strand and the $\alpha$A helix of the Abl SH2 domain (Figure S5C). Pro60 and Tyr62 make most of the DE loop contacts, together burying more than 150 Å² of surface area.

The second surface concavity is bounded on one side by $\beta$ strand B of the Abl SH2 domain, on the other by $\alpha$ helix B, and from above and below by the N-terminal and C-terminal tails of the Abl SH2 domain (Figure S5A, cyan box). Phe87 of the 7c12 FG loop penetrates deep into the center of this pocket, burying 133 Å² of surface area on its own. Other residues in the FG loop (Phe88, Pro89), Val38, and the aliphatic portion of Lys39 of the BC loop form a ring of hydrophobic contacts at the periphery of this surface pocket (Figure SSD). Together, these residues contribute nearly 300 Å² to total monobody surface area burial.

The interface observed in the crystal structure is also consistent with the strong negative effect of the I164E mutant on 7c12-SH2 interaction (Figure 5B). Ile164 is located at the edge of the 7c12-binding interface and contributes 29 Å² of surface to the interface. It makes hydrophobic interactions with Tyr62 of the DE loop (Figure S5C). These features rationalize the ~400-fold reduction in binding affinity by the I164E mutation (Figure 6B).

In order to further confirm the authenticity of the interaction interface observed in the crystal structure, we used nuclear magnetic resonance (NMR) spectroscopy to conduct site mapping. The Abl SH2 backbone amide resonances most greatly affected by the presence of 7c12, as measured in 15N HSQC experiments, are in good agreement with portions of the SH2 domain that are contacted by 7c12 in the crystal structure (Figure S5F), suggesting that the interface observed in the crystal structure corresponds to the actual solution-phase interaction. To further validate the crystal structure using an independent experimental approach, we mutated each of the loop regions individually back to the template sequence and
Figure 6. Targeting the SH2-Kinase Domain Interface with the Engineered Monobody Protein 7c12 Leads to Bcr-Abl Inhibition
(A) In vitro kinase activity of immunoprecipitated Bcr-Abl WT, I164E, T315I, and T315I/I164E proteins was assayed in the presence of the indicated concentrations of recombinant 7c12. FKBP12 was used as a control recombinant protein. Activity of each Bcr-Abl mutant-buffer control was normalized to 1. Significance levels are indicated (ns: not significant, *p < 0.05, **p < 0.01, ***p < 0.001). The bar graph shows averages ± SD from at least three independent experiments done in triplicate. See also Figure S4.

(B) Competition phage ELISA of the 7c12 monobody. Phages displaying the 7c12 monobody were bound to GST-Abl SH2 WT or I164E protein. Unbound phages were exposed to immobilized Abl SH2 domain and detected using an anti-phage antibody. Values are normalized to the intensity of the ELISA signal in the absence of a competitor.

(C) Crystal structure of the complex of the monobody 7c12-Abl SH2 domain complex (PDB entry 3T04). Ile164 is part of the interface and shown in red. Lower panel: Superposition of the 7c12-Abl SH2 complex and the active Abl structure. The surface of the Abl kinase domain is shown to highlight the incompatibility of simultaneous binding of 7c12 and the Abl kinase domain to the SH2 domain. See Table S1 and Figure S5 for details.

(D) Superposition of the 7c12-Abl SH2 domain complex (PDB entry 3T04) and the HA4-Abl SH2 complex (PDB entry 3K2M) crystal structures. HA4 and 7c12 are shown in blue and orange, respectively. The Gly-Ser linker between HA4 and 7c12 is indicated as a dotted red line. Arg171 in the Abl SH2 domain is shown to indicate the location of the phosphotyrosine-binding pocket. Residues Tyr88, Tyr172, and Phe197 were mutated to abolish binding to the Abl SH2 domain. See also Figure S5.

(E) In vitro kinase activity of immunoprecipitated Bcr-Abl WT protein was assayed in the presence of the indicated concentrations of recombinant HA4-7c12 WT or the nonbinding Y88A/Y172E/F197K mutant protein. Significance levels are indicated (ns: not significant, *p < 0.05, **p < 0.01, ***p < 0.001). The bar graph shows averages ± SD from one representative experiment done in triplicate. See also Figure S6.
measured the binding affinity of these mutants. In each case, the mutant-Abl SH2 domain interaction was at least 100 times weaker than the wild-type 7c12-Abl SH2 interaction (data not shown). These results are consistent with the crystal structure, in which each loop makes a significant contribution to the 7c12-Abl SH2 interaction. Together, these studies provide significant validation of the observed crystal structure interface.

Comparison of the 7c12-Abl SH2 Interface to the Abl SH2-Kinase Domain Interface

We next compared the Abl SH2-kinase domain interface with the 7c12-Abl SH2 interface (Figures 6C and S5). The size of the SH2-kinase domain interface is 1030 Å², ~75% of that of the 7c12-Abl SH2 interface. More than half of the total surface area of the SH2-kinase interface overlaps with the 7c12-SH2 domain interface centered on β strand B of the Abl SH2 domain (Figures S5G and S5H). This significant overlap in the 7c12-Abl SH2 and Abl SH2-kinase interfaces strongly suggests that the binding of the SH2 domain to the kinase domain and to 7c12 are mutually exclusive (Figures 6C, S5G, and S5H). The incompatibility of simultaneous binding of the SH2 to both the kinase domain and 7c12, therefore, likely explains the observed inhibition of Bcr-Abl kinase activity, as full 7c12 binding requires the disruption of the SH2-kinase domain interface. Given the theoretical difficulty of competing intermolecularly with an ~1100 Å² intramolecular protein-protein interaction and the partial occlusion of the 7c12-binding site on the SH2 domain by the kinase domain, we consider the degree of inhibition that is achieved by the 7c12 monobody to be symptomatic and strongly indicative of a specific vulnerability.

Improved Targeting of the SH2 Interface with a Tandem Fusion of the HA4 and 7c12 Monobodies

Despite the clear demonstration of the general feasibility of targeting the SH2-kinase interface using 7c12, we aimed at improving its biological potency. Superposition of the structure of the previously characterized HA4 monobody bound to the Abl SH2 domain (Wojcik et al., 2010) with the 7c12-Abl SH2 structure reveals that the two monobodies bind on opposite faces of the SH2 domain with no overlap (Figures 6D and S5E). This arrangement is consistent with the selection scheme employed for the generation of 7c12, in which HA4 was used as a competitor, and with sandwich-ELISA data indicating that HA4 and 7c12 can bind simultaneously to the same Abl SH2 domain molecule (data not shown). HA4 binds with low nanomolar affinity to the phosphotyrosine-binding pocket of the Abl SH2 domain, which is not part of an intramolecular interaction in Bcr-Abl and is able to effectively outcompete phosphotyrosine ligand binding (Wojcik et al., 2010). For these reasons, we attempted to link HA4 and 7c12 in tandem, which should increase the local concentration of 7c12 in proximity to the SH2-kinase domain interface and further enhance the specificity toward the Abl SH2 domain. A 19 amino acid Gly-Ser linker was used to bridge the C terminus of HA4 to the N terminus of 7c12, based on structural modeling (Figure 6D). As negative controls, we introduced point mutations in both parts of the HA4-7c12 tandem monobody. For HA4, we used the Y88A (Y87A in the original numbering scheme) mutation that was previously shown to reduce binding to the Abl SH2 domain >1000-fold (Wojcik et al., 2010). We also designed a double point mutation (Y172E/F179K; Y62E/F87K) in the original numbering scheme, Figure S5) for the 7c12 part, which is located at structurally central positions of the 7c12-Abl SH2 interface and showed a strong reduction in binding in pull-down experiments (data not shown). We tested the HA4-7c12 tandem monobody in Bcr-Abl in vitro kinase assays. We observed a strong inhibition of Bcr-Abl activity with low micromolar concentrations of the HA4-7c12 tandem monobody, whereas the nonbinding Y88A/Y172E/F179K mutant failed to inhibit Bcr-Abl activity (Figure 6E). Importantly, the degree of inhibition of Bcr-Abl activity achieved by HA4-7c12 was comparable to that upon introduction of the I164E mutant (Figures 1C and 2A). HA4-7c12 was also able to inhibit Bcr-Abl T231R, although to a lesser degree than Bcr-Abl WT (Figure S6). This indicates that the tandem monobody may lead to a complete disruption of the Bcr-Abl kinase domain interface.

The HA4-7c12 Tandem Monobody Strongly Inhibits Cellular Bcr-Abl Activity and Induces Apoptosis in CML Cells

Finally, we tested whether the HA4-7c12 tandem monobody would also inhibit Bcr-Abl activity in CML cells. Transient expression of a HA4-7c12-GFP fusion protein in the Bcr-Abl-positive CML cell line K562 led to a strong reduction of activation loop (Tyr412) phosphorylation of Bcr-Abl (Figure 7A). This effect was dependent on both HA4 and 7c12 moieties of the tandem monobody, as expression of point mutants that abolish binding of either HA4 (Y88A) or 7c12 (Y172E/F197K) or both to the Abl SH2 domain did not show this effect (Figure 7A).

We next tested whether the HA4-7c12-induced decrease in Bcr-Abl activity with HA4-7c12 would result in cell death. Indeed, K562 cells expressing the HA4-7c12 tandem monobody showed high amounts of apoptosis, as measured by TUNEL and cleaved caspase 3 staining (Figures 7B and S7A). Again, this effect was not evident when the nonbinding mutant was used.

Next, we asked whether HA4-7c12 would inhibit Bcr-Abl-induced transformation of primary murine bone marrow cells. In contrast to the nonbinding mutants, bicistronic expression of Bcr-Abl and GFP-HA4-7c12 WT severely impaired cytokine-independent colony formation in semisolid media (Figure 7C).

Finally, we tested whether HA4-7c12 would induce apoptosis in primary bone marrow or peripheral blood cells from CML patients at different stages of the disease (Table S2). Lentiviral expression of HA4-7c12 induced an ~65% increase in apoptotic cells over the nonbinding mutant HA4 Y88A-7c12-Y172E/F197K in cells from patients in chronic phase (Figure 7D, left panel). This increase was comparable to the induction of apoptosis upon treatment of the same cultures with 2 μM nilotinib for 5 days (41%). Similar results were obtained when cells from patients in the accelerated phase of the disease were used (Figure 7D, right panel). Here, nilotinib treatment led to a 40% increase whereas expression of HA4-7c12 induced a 49% increase in apoptosis.

Together, these data show that Bcr-Abl activity can be inhibited by targeting the SH2-kinase interface using FN3-based monobodies in CML cell lines, as well as in primary cells from CML patients.
DISCUSSION

In this study, we have identified the SH2-kinase domain interface as a critical structural feature that is important for the adoption and maintenance of the active conformation of Bcr-Abl. We show that disruption of this interface completely abolishes Bcr-Abl leukemogenicity. Therefore, the SH2-kinase domain interface in Bcr-Abl represents an attractive “druggable” target in addition to its ATP- and myristate-binding sites. As a molecular tool, we developed the FN3-based monobody 7c12 and the tandem monobody HA4-7c12 that showed strong inhibition of Bcr-Abl activity in vitro and induced apoptosis in CML cells. The HA4-7c12 fusion is an example of the use of two FN3 monobodies in tandem to achieve a higher level of target inhibition. Although we show that lentiviral delivery of the HA4-7c12 cDNA was able to induce apoptosis in primary cells from CML patients, difficulties with intracellular delivery of the HA4-7c12 protein will most probably limit or preclude the use of monobodies as drug-like molecules in clinical applications. In contrast, the exquisite affinity and specificity of HA4-7c12 for Bcr-Abl suggest general utility of monobodies as target validation tools for preclinical studies.

Recent data confirmed evidence for a positive role of the SH2 domain on the adjacent tyrosine kinase domain in selected cytoplasmic tyrosine kinases (Filippakopoulos et al., 2008; Mikkola and Gahmberg, 2010; Joseph et al., 2007), originally identified in the v-Fps/Fes oncoprotein (Sadowski et al., 1986). Despite this conserved allosteric regulatory property of the SH2 domain, the surfaces involved in establishing the interface between the SH2 domain and the tyrosine kinase domain N lobe appear to be diverse in terms of biophysical properties, size, and affinity among different tyrosine kinases. The underlying structural mechanism responsible for the activation of the Abl kinase domain by its SH2 domain is still elusive and should be the subject of an independent study. However, the I164E mutation disrupts the SH2-kinase domain interface while leaving the core function of the SH2 domain—binding of phosphotyrosine ligands—unaffected. Previous studies have attempted to address the role of the SH2 domain for oncogenic transformation and leukemogenicity of Bcr-Abl either by mutating the conserved Arg171 in the phosphotyrosine-binding pocket or by deleting the entire domain (Ilaria and Van Etten, 1995; Roumiantsev et al., 2001). However, the widely used mutation of Arg171 is associated with a loss of the integrity of the SH2 domain (Figure S1 and data not shown). Therefore, as in the case of deletion of the entire domain, both the phosphotyrosine-binding function as well as the maintenance of the SH2-kinase domain interface are likely to be compromised upon introduction of the Arg171 mutation. Thus, the observed effects on transformation and leukemogenicity likely reflect a combination of multiple effects caused by interference with the protein architecture.

As interference with the SH2-kinase domain interface leads to a dramatic reduction in Bcr-Abl activity, one would expect a uniform decrease in the activation of the major pathways that are activated by Bcr-Abl. Instead, we observed an almost exclusive loss of STAT5 activation. STAT5 is a central component that is required for the induction and maintenance of CML induced by Bcr-Abl (Nieborowska-Skorska et al., 1999; Hoelbl et al., 2010). Therefore, it is tempting to speculate that the inability of Bcr-Abl I164E to induce CML is caused by its inability to activate STAT5. It has been shown that even short-term blockage of Bcr-Abl action resulted in severe and complete inhibition of STAT5 activity and target gene expression (Shah et al., 2008; Hantschel et al., 2008). In contrast, other pathways, including the Ras-MAPK or the PI3K-Akt pathways, were not compromised strongly. This may be the reason that Bcr-Abl I164E, although not leukemogenic, may confer cytokine independence to Ba/F3 or UT-7 cells.

Together, our work shows that interfering with the SH2-kinase domain interface can allosterically inhibit Bcr-Abl activity. It should be feasible to develop a small molecule that interferes with this SH2-kinase domain interaction. Such allosteric modulators could be of either antagonistic or agonistic nature depending on the targeted surface and binding mode. This may represent an attractive option for patients with chronic phase CML that only achieve a suboptimal response or are resistant to TKI therapy, as well as for patients with advanced stage CML or Ph-positive acute lymphoblastic leukemia.

EXPERIMENTAL PROCEDURES

Cells

Cell lines or primary cells were transduced with the indicated constructs using pMSCV-ires-GFP-based retroviral vectors for 72 hr in the presence of 5 µg/ml of Polybrene. Cell lines were cultured in complete growth media while primary cells were cultured in IMDM supplemented with 10% FBS, 1% non-essential amino acids, and 1% penicillin/streptomycin.

Figure 7. The Tandem Monobody HA4-7c12 Strongly Inhibits Cellular Bcr-Abl Kinase Activity and Induces Apoptosis in CML Cell Lines and Primary Cells

(A) K562 cells were transiently transfected with the indicated HA4-7c12-GFP fusion constructs, and Bcr-Abl Tyr412 phosphorylation was measured using flow cytometry. Left panel: Histograms of Bcr-Abl pY412 fluorescence intensities of the GFP-positive fraction of cells transfected with the indicated constructs. Right panel: Quantitation of Bcr-Abl pY412 fluorescence. The intensities were normalized to K562 cells treated with nilotinib (complete inhibition—arbitrarily set to 0; Figure S5) and cells transfected with the nonbinding mutant HA4 Y88A-7c12 Y172E/F197K (no inhibition—arbitrarily set to 1) (n = 3).

(B) K562 cells treated as described in (C) were analyzed for apoptosis using TUNEL staining. Left panel: Histograms of TUNEL fluorescence of the GFP-positive fraction of cells transfected with the indicated constructs. Right panel: Quantitation of TUNEL-positive cells (n = 3). The intensities were normalized to K562 cells treated with nilotinib (complete inhibition—arbitrarily set to 100%; Figure S7C) and mock-transfected cells (arbitrarily set to 0%) (n = 3).

(C) Primary murine bone marrow cells were transduced with the indicated retroviral constructs. GFP-positive cells were seeded in semisolid medium, and cytokine-independent colonies were scored.

(D) Primary cells from CML patients from chronic phase (left panel) or accelerated phase (right panel) were transduced with lentiviruses encoding HA4-7c12 WT or HA4 Y88A-7c12 Y172E/F197K. Parallel cultures from the same patients were treated with nilotinib for 5 days. Apoptosis was measured after 5 days via cleaved caspase staining by FACs. Levels of apoptosis in the GFP-positive fraction of cells transfected with HA4 Y88A-7c12 Y172E/F197K or in untreated cells were normalized to 1. p values: Chronic phase (five patients): 0.0007; accelerated phase (two patients): 0.011; one-way ANOVA.

In all panels, error bars represent SD. See Table S2 and Figure S7 for details.
of IL-3, IL-6, SCF, and 7 μg/ml polybrene. For transient monobody expression, 1 × 10^6 K562 cells were transfected with 5 μg of expression vectors encoding GFP fusion constructs of HA4-7c12 and mutants thereof using the Nucleofector Kit V (Amaxa), applying program T-016. Samples were harvested 48 hr later. Primary CML cells were isolated from bone marrow or peripheral blood samples of patients with Ph-chromosome-positive CML at time of diagnosis. All patients gave written informed consent before blood or bone marrow was obtained. Cells were transfected with concentrated lentiviral supernatants via spinoculation (1000 × g, 90 min) at a multiplicity of infection (moi) of 20 and cultivated in RPMI 1640 medium plus 10% FCS and 100 ng/ml human Interleukin 3 (PeproTech). The study was approved by the Institutional Review Board (IRB) of the Medical University of Vienna.

**Primary Cell Transformation Assay and Bone Marrow Transplantation**

GFP-positive cells were isolated using fluorescence-activated cell sorting (FACS) and seeded in cytokine-free methylcellulose, and colonies were scored 8 days later. For bone marrow transplantation studies, transduced cells were injected into lethally irradiated (10 Gy) WT recipients via the tail vein. Peripheral blood samples of animals were regularly scored for the presence of GFP-Bcr-Abl-positive cells. Upon signs of sickness, mice were sacrificed, and hemato-poietic organs were analyzed for leukemic cells by FACS using fluorescently labeled antibodies against GR-1, Mac-1, CD19, and CD3. Tissues were fixed in paraformaldehyde prior to sectioning and staining with hematoxylin/eosin.

**Kinase Assays**

Immunoprecipitation of Bcr-Abl/c-Abl protein and Abl in vitro kinase assay were carried out as described previously (Hantschel et al., 2003). Immunoprecipitated Bcr-Abl proteins were resuspended in kinase assay buffer containing the indicated concentrations of tyrosine kinase inhibitor or recombinant monobody protein. A peptide with the preferred Abl substrate sequence carrying an N-terminal biotin (biotin-GGALAIYAPFKK-amide) was used as a substrate. The terminated reaction was spotted onto a SAM2 Biotin Capture membrane (Promega) and further treated according to the instructions of the manufacturer. The relative amount of immunoprecipitated Abl protein was determined by immunoblotting and subsequent relative quantification using the Li-Cor Odyssey system.

**Induced Tethering of the Abl SH2 Domain to the Abl Kinase Domain**

For the experiments described in Figure 2C, we used the Regulated Heterodimerization Kit (Ariad Inc. FRB was fused to the N terminus of the SH2 domain and FKBP12 to the N terminus of the kinase domain and transiently transfected in HEK293 cells along with HA-Paxillin. Forty-eight hours after transfection, we induced dimerization of FRB-SH2 domains with FKBP-kinase domain constructs by treating cells with 2 μM of AP21967 for 3 hr.

**Monobody Selection and Preparation**

To identify monobodies to the kinase-interaction surface of the Abl SH2 domain, a phage-display library was sorted using biotinylated Abl SH2 as a target in the presence of a 5-fold excess of the monobody HA4, which binds to the phosphopeptide interface of the SH2 domain (Wojcik et al., 2010). Otherwise, selection, cloning, and expression of the 7c12 monobody were carried out as described previously (Koide and Koide, 2007, Wojcik et al., 2010). Proteins were produced with an N-terminal His$_6$-tag and purified using a Ni$_2$-NTA column (Qiagen). Uppon signs of sickness, mice were sacrificed, and hematopoietic organs were analyzed for leukemic cells by FACS using fluorescently labeled antibodies against GR-1, Mac-1, CD19, and CD3. Tissues were fixed in paraformaldehyde prior to sectioning and staining with hematoxylin/eosin.

**Intracellular Flow Cytometry**

Cells were fixed in 3.2% paraformaldehyde and stored in Methanol, followed by staining with antibodies recognizing Stat5 phosphorylated on Tyr697 (BD Biosciences), CrkL phosphorylated on Tyr207 (Cell Signaling), or Abl phosphorylated on Tyr412 (Cell Signaling) followed by a PE-conjugated goat anti-rabbit secondary antibody (Imgenex). For analysis of apoptosis, cells were stained with antibodies against cleaved caspase 3 (Cell Signaling) or subjected to TUNEL followed by staining with a PE-conjugated anti-BrdU antibody according to the manufacturer’s instructions (BioVision).

**SUPPLEMENTAL INFORMATION**

Supplemental Information includes Extended Experimental Procedures, seven figures, and two tables and can be found with this article online at doi:10.1016/j.cell.2011.08.046.

**ACKNOWLEDGMENTS**

This work was supported by the Austrian Academy of Sciences, in part by grants from the Austrian Science Fund (FWF) (#P18737 to O.H., I.K., and G.S.-F. and #P22282 to F.G.), a Terry Fox Programme Project grant from the Canadian Cancer Society and CIHR (#MOP-8849 to T.P.), an EMBO short-term fellowship (#ASTF 293.00-2009 to J.W.), the National Institutes of Health (R01-GM72688 and R21-CA132700 to S.K. and T32GM07281 to J.W.), and the University of Chicago Cancer Research Center (to S.K.). Part of the work was conducted at the Advanced Photon Source on the Northeastern Collaborative Access Team beamslines, which are supported by award RR-15301 from the National Center for Research Resources at NIH. Use of the Advanced Photon Source is supported by the U.S. Department of Energy, Office of Basic Energy Sciences, under Contract No. DE-AC02-06CH11357. We wish to thank all members of the participating laboratories for continuous support and discussions, D. Printz (CRI Vienna) for expert FACS sorting, V. Komnenovic (IMBA Vienna) for help with histology, H. Pickersgill for help with manuscript preparation, and K. De Keersmaecker and T. Buermckatemmer for critical reading of the manuscript. P.V. received a research grant and honorarium from Novartis and a research grant and honorarium from BMS. This work is dedicated to the memories of Maggie Pawson and Hartmut Beug.

Received: October 28, 2010
Revised: June 7, 2011
Accepted: August 31, 2011
Published: October 13, 2011

**REFERENCES**

Belshaw, P.J., Ho, S.N., Crabtree, G.R., and Schreiber, S.L. (1996). Controlling protein association and subcellular localization with a synthetic ligand that induces heterodimerization of proteins. Proc. Natl. Acad. Sci. USA 93, 4604–4607.

Daley, G.G., Van Etten, R.A., and Baltimore, D. (1990). Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 247, 824–830.

De Keersmaecker, K., Versele, M., Cools, J., Superti-Furga, G., and Hantschel, O. (2008). Intrinsic differences between the catalytic properties of the oncogenic NUP214-ABL1 and BCR-ABL1 fusion protein kinases. Leukemia 22, 2208–2216.

Deininger, M., Buchdunger, E., and Druker, B.J. (2005). The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 105, 2640–2653.

Filippakopoulos, P., Koffer, M., Hantschel, O., Gish, G.D., Grebien, F., Salah, E., Neudecker, P., Kay, L.E., Turk, B.E., Superti-Furga, G., et al. (2008). Structural coupling of SH2-kinase domains links Fes and Abl substrate recognition and kinase activation. Cell 134, 793–803.

Filippakopoulos, P., Müller, S., and Knapp, S. (2009). SH2 domains: modulators of nonreceptor tyrosine kinase activity. Curr. Opin. Struct. Biol. 19, 643–649.

Hantschel, O., and Superti-Furga, G. (2004). Regulation of the c-Abl and Bcr-Abl tyrosine kinases. Nat. Rev. Mol. Cell Biol. 5, 33–44.

Hantschel, O., Nagar, B., Guettler, S., Kretzschmar, J., Dorey, K., Kuriyan, J., and Superti-Furga, G. (2003). A myristoyl/phosphotyrosine switch regulates c-Abl. Cell 112, 845–857.
Hantschel, O., Gsteoetterbauer, A., Collinge, J., Kaupe, I., Bilban, M., Burkard, T.R., Valant, P., and Superti-Furga, G. (2008). The chemokine interleukin-8 and the surface activation protein CD69 are markers for Bcr-Abl activity in chronic myeloid leukemia. Mol. Oncol. 2, 272–281.

Hochhaus, A., O’Brien, S.G., Guilhot, F., Druker, B.J., Branford, S., Foroni, L., Goldman, J.M., Müller, M.C., Radich, J.P., Rudoltz, M., et al; IRIS Investigators. (2009). Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 23, 1054–1061.

Hoeibl, A., Schuster, C., Kovacic, B., Zhu, B., Wickre, M., Hoezl, M.A., Fajmann, S., Grebien, F., Warsch, W., Stengl, G., et al. (2010). Statis is indispensable for the maintenance of bcr abl-positive leukemia. EMBO Mol Med 2, 98–110.

Hiliar, R.L., Jr., and Van Etten, R.A. (1995). The SH2 domain of P210BCR/ABL is not required for the transformation of hematopoietic factor-dependent cells. Blood 86, 3897–3904.

Jabbour, E., Hochhaus, A., Cortes, J., La Rosée, P., and Kantarjian, H.M. (2010). Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history. Leukemia 24, 6–12.

Joseph, R.E., Min, L., Xu, R., Musselman, E.D., and Andreotti, A.H. (2007). A remote substrate docking mechanism for the tec family tyrosine kinases. Biochemistry 46, 5955–5963.

Koide, A., and Koide, S. (2007). Monobodies: antibody mimics based on the scaffold of the fibronectin type III domain. Methods Mol. Biol. 352, 95–109.

Mayer, B.J., Hirai, H., and Sakai, R. (1995). Evidence that SH2 domains promote processive phosphorylation by protein-tyrosine kinases. Curr. Biol. 5, 296–305.

McWhirter, J.R., Galasso, D.L., and Wang, J.Y. (1993). A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins. Mol. Cell. Biol. 13, 7587–7595.

Mikkola, E.T., and Gahmberg, C.G. (2010). Hydrophobic interaction between the SH2 domain and the kinase domain is required for the activation of Csk. J. Mol. Biol. 399, 618–627.

Million, R.P., and Van Etten, R.A. (2000). The Grb2 binding site is required for the induction of chronic myeloid leukemia-like disease in mice by the Bcr/Abl tyrosine kinase. Blood 96, 664–670.

Nagar, B., Hantschel, O., Young, M.A., Scheffzek, K., Veach, D., Bormann, W., Clarkson, B., Superti-Furga, G., and Kuriyan, J. (2003). Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell 112, 859–871.

Nagar, B., Hantschel, O., Seeliger, M., Davies, J.M., Weiss, W.J., Superti-Furga, G., and Kuriyan, J. (2006). Organization of the SH3-SH2 unit in active and inactive forms of the c-Abl tyrosine kinase. J. Mol. Biol. 352, 5595–5603.

Nagar, B., Hantschel, O., Young, M.A., Scheffzek, K., Veach, D., Bormann, W., Clarkson, B., Superti-Furga, G., and Kuriyan, J. (2003). Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell 112, 859–871.

Nieborowska-Skorska, M., Wasik, M.A., Slupianek, A., Salomoni, P., Kitamura, T., Calabretta, B., and Skorski, T. (1999). Signal transducer and activator of transcription (STAT)5 activation by BCR/ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR/ABL and is required for leukemogenesis. J. Exp. Med. 189, 1229–1242.

Pawson, T., Gish, G.D., and Nash, P. (2001). SH2 domains, interaction modules and cellular wiring. Trends Cell Biol. 11, 504–511.

Perrotti, D., Jamieson, C., Goldman, J., and Skorski, T. (2010). Chronic myeloid leukemia: mechanisms of blastic transformation. J. Clin. Invest. 120, 2254–2264.

Quintas-Cardama, A., Kantarjian, H., and Cortes, J. (2007). Flying under the radar: the new wave of BCR-ABL inhibitors. Nat. Rev. Drug Discov. 6, 834–844.

Ren, R. (2005). Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukemia. Nat. Rev. Cancer 5, 172–183.

Roumiantsev, S., de Aos, I.E., Varticovski, L., Ilaria, R.L., and Van Etten, R.A. (2001). The src homology 2 domain of Bcr/Abi is required for efficient induction of chronic myeloid leukemia-like disease in mice but not for lymphoid leukemogenesis or activation of phosphatidylinositol 3-kinase. Blood 97, 4–13.

Sadowski, I., Stone, J.C., and Pawson, T. (1986). A noncatalytic domain conserved among cytoplasmic protein-tyrosine kinases modifies the kinase function and transforming activity of Fujinami sarcoma virus P130gag-fps. Mol. Cell. Biol. 6, 4386–4408.

Sattler, M., Mohi, M.G., Pride, Y.B., Quinnan, L.R., Malouf, N.A., Podar, K., Gesbert, F., Iwasaki, H., Li, S., Van Etten, R.A., et al. (2002). Critical role for Gab2 in transformation by BCR/ABL. Cancer Cell 1, 479–492.

Schindler, T., Bornmann, W., Pellicena, P., Miller, W.T., Clarkson, B., and Kuriyan, J. (2000). Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 289, 1938–1942.

Shah, N.P., and Sawyers, C.L. (2003). Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias. Oncogene 22, 7389–7395.

Shah, N.P., Kasap, C., Weier, C., Balbas, M., Nicoll, J.M., Bleickardt, E., Nicaise, C., and Sawyers, C.L. (2008). Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis. Cancer Cell 14, 485–493.

Sherbenou, D.W., Hantschel, O., Kaupe, I., Willis, S., Burm, T., Turaga, L.P., Lange, T., Dao, K.-H., Press, R.D., Druker, B.J., et al. (2010). BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib. Blood 116, 3278–3285.

Vajpai, N., Strauss, A., Findrich, G., Cowan-Jacob, S.W., Manley, P.W., Grzesiek, S., and Janhke, W. (2008). Solution conformations and dynamics of ABL kinase-inhibitor complexes determined by NMR. Biochemistry 47, 9743–9752.

Wong, S., and Witte, O.N. (2004). The BCR-ABL story: bench to bedside and back. Science 306, 319–328.

Wong, S., and Witte, O.N. (2004). The BCR-ABL story: bench to bedside and back. Annu. Rev. Immunol. 22, 247–306.

Zhang, J., Adrians, F.J., Jahne, W., Cowan-Jacob, S.W., Li, A.G., Iacob, R.E., Sim, T., Powers, J., Dierks, C., Sun, F., et al. (2010). Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. Nature 463, 501–506.